Company Website

Contact Information:

Holly Wayne
hwayne@rigel.com
608-852-0739

Virtual Exhibit Hall Home

Rigel Pharmaceuticals is a biotechnology company dedicated to improving the lives of patients through the discovery, development, and commercialization of novel small molecule drugs. Rigel is focused on immune and hematologic disorders, cancer, and rare diseases and see great opportunity to help patients who have diseases where few to no approved treatment options exist.
Rigel's first FDA approved product TAVALISSE® (fostamatinib disodium hexahydrate) tablets was approved in 2018.
Please visit www.TAVALISSEhcp.com to see the full Prescribing Information and learn more.

Additional Information: 

Zoom Link: https://rigel.zoom.us/j/91865859340?pwd=dytHdkpnWENZZ2JueitEL2pJR1QyQT09
Meeting ID: 918 6585 9340
Passcode: 606208

Promotional Links:
Patient Website
BJH Publication
TAVALISSE Resources
TAVALISSE Patient Onboarding Materials
TAVALISSE Full Prescribing Information

Rigel Regional Contacts - requires logging in to view content
TAVALISSE Together - Patient Support - requires logging in to view content
TAVALISSE 2nd Line Patient Case
Video